Phibro Animal Health (PAHC) Non-Current Debt (2013 - 2026)
Phibro Animal Health (PAHC) recorded quarterly Non-Current Debt of $115.0 million in Q1 2026, down 80.95% quarter-over-quarter from $603.6 million in Q4 2025, and down 81.43% on a YoY basis from $619.2 million in Q1 2025.
Phibro Animal Health (PAHC) Non-Current Debt (2013 - 2026) Analysis & Trends
Phibro Animal Health's Non-Current Debt history runs 14 years deep, the most recent figure standing at $115.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 81.43% year-over-year to $115.0 million; the TTM figure through Mar 2026 stood at $115.0 million (down 81.43% YoY), while the FY2025 annual figure was $87.0 million, down 50.57% from the prior year.
- Non-Current Debt was $115.0 million for Q1 2026 at Phibro Animal Health, down from $603.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $622.9 million in Q4 2024 to a low of $87.0 million in Q2 2025.
- Historically, Non-Current Debt has averaged $292.0 million across 5 years, with a median of $193.0 million in 2023.
- The sharpest annual moves came in 2024 and 2026: Non-Current Debt surged 312.5% in 2024, then slumped 81.43% in 2026.
- A 5-year view of Non-Current Debt shows it stood at $276.8 million in 2022, then slumped by 45.45% to $151.0 million in 2023, then soared by 312.5% to $622.9 million in 2024, then slipped by 3.09% to $603.6 million in 2025, then plunged by 80.95% to $115.0 million in 2026.
- The last three Non-Current Debt figures came in at $115.0 million (Q1 2026), $603.6 million (Q4 2025), and $609.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 569.60 Mn |
| 10 | Phibro Animal Health | 1.32 Bn | 1.24 Bn | 125.68 Mn | 115.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.00 Mn |
| Mar 31, 2026 | 115.00 Mn |
| Dec 31, 2025 | 603.60 Mn |
| Dec 31, 2025 | 603.60 Mn |
| Sep 30, 2025 | 609.52 Mn |
| Sep 30, 2025 | 609.52 Mn |
| Jun 30, 2025 | 87.00 Mn |
| Jun 30, 2025 | 87.00 Mn |
| Mar 31, 2025 | 619.16 Mn |
| Mar 31, 2025 | 619.16 Mn |
| Dec 31, 2024 | 622.88 Mn |
| Dec 31, 2024 | 622.88 Mn |
| Sep 30, 2024 | 287.67 Mn |
| Sep 30, 2024 | 287.67 Mn |
| Jun 30, 2024 | 176.00 Mn |
| Jun 30, 2024 | 176.00 Mn |
| Mar 31, 2024 | 165.00 Mn |
| Mar 31, 2024 | 165.00 Mn |
| Dec 31, 2023 | 151.00 Mn |
| Dec 31, 2023 | 151.00 Mn |